There was no significant change in the γGT levels .
Significant differences were not found .
CONCLUSION Silymarin minimally reduced , but without clinical relevance , the serum levels of ALT and AST .
AIM To evaluate the effect of silymarin on the serum levels of alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) and gamma glutamyl transpeptidase ( γGT ) in patients with liver diseases .
Silymarin in treatment of non-alcoholic steatohepatitis: A randomized clinical trial.
BACKGROUND No pharmacologic agents have been approved for the treatment of non-alcoholic steatohepatitis ( NASH ) that is common in our region . The present study was design ed to evaluate the efficacy of silymarin , a known herbal drug , in the treatment of NASH . METHODS This clinical -trial study was conducted on 64 patients with NASH who were r and omly divided as case group ( 33 ) and control group ( 31 ) . Abdominal sonography and persistent elevation in levels of aspartate aminotransferase ( AST ) and alanine aminotransferase ( ALT ) more than 1.2 times of the upper normal limit within the last six months were selected as inclusion criteria . They were advised to take low-fat , low carbohydrate diet , do regular sport activity to lose weight up to 4 Kg . Patients in the case group received 210 mg/day silymarin orally for 8 weeks and those in the control group received placebo . After 8 weeks , the patients were reevaluated and their AST and ALT levels were measured . This study was registered in the Iranian Registry of Clinical Trial ( www.i rct .ir ) with registration number ID : I RCT 201202159018N1 . RESULTS The mean age of patients in case and control groups was 43.6±8.3 and 39.4±10.5 years , respectively . Their BMI were 27.4±1.7 and 27.5±1.9 , respectively . Their weights were also 79±9.2 and 76.9±9.5 kg , respectively . Serum concentrations of ALT were 91.3±21.3 and 38.4±11.8 in case group before and after the study respectively , whiles the figures were 84.6±23.3 and 52.3±29 in the control group ( P=0.026 ) . The same trend was seen for AST ( P=0.038 ) . CONCLUSION The patients who had taken silymarin experienced more notable fall in hepatic enzymes
There was no significant change in the γGT levels .
Significant differences were not found .
CONCLUSION Silymarin minimally reduced , but without clinical relevance , the serum levels of ALT and AST .
AIM To evaluate the effect of silymarin on the serum levels of alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) and gamma glutamyl transpeptidase ( γGT ) in patients with liver diseases .